Additionally,the dual agonist tirzepatide (targeting GLP-1R and GIPR) was recentlyapproved for the treatment of obesity and type 2 diabetes. Furthermore, thetriple agonist retatrutide (targeting GLP-1R, GIPR, and GCGR) hasshown remarkable effects on weight loss and is currently in advancedclinical trials. Here, GLP1R is linked to obesity disorder.